Logistic regression analyses confirmed that Sema4D expression is significantly associated with poor response to induction therapy.<h4>Conclusion</h4> PBMCs' Sema4D expression can be considered a potential marker for predicting the response to induction therapy in pediatric patients with B-ALL. The gene discussed is SEMA4D; the disease is acute lymphoblastic leukemia.